Are you afraid of having your blood drawn? But what if the blood test could detect cancer causing genetic mutations and viruses, and allow for early treatment?  

I’m asking this because we are going to look at a company called Lucence, which makes blood tests to detect cancers. 

Founded in 2016, Lucence was spun off from the Agency for Science, Technology and Research (A*STAR). 

It had in 2019 unveiled a blood test called LiquidHALLMARK that detects 14 types of cancers, 50 genetic mutations and two viruses. Lucence had said then that LiquidHALLMARK is the world's first blood test that simultaneously detects both cancer-causing genetic mutations and viruses with 99.9 per cent accuracy.

But how much money does this represent? How does the company assess its competition, and how is it treading the fine line in ensuring that it achieves the profits it wants yet ensure that the tests remain affordable and accessible? 

On Under the Radar, Drive Time’s finance presenter Chua Tian Tian posed these burning questions to Dr Tan Min-Han Founder, CEO and Medical Director at Lucence.